It’s been a question posed for years by many around the New York biotech scene: What is going on with the New York City Economic Development Corp.’s $150 million biotech fund, which was formed in 2013 but hadn’t made an investment?
Finally, today, there’s an answer. A small piece of the money from the NYCEDC’s NYC Life Sciences Fund is going to an ambitious new startup called HiberCell, which is focused on routing out the small numbers of dormant tumor cells that lurk in patients in remission and turn into deadly, recurring cancers.
“This definitely took time, I think we’ll acknowledge… Read more »
UNDERWRITERS AND PARTNERS
Categories: ARCH Venture Partners, Boston blog main, Boston top stories, Celgene, Deals, Eli Lilly, Flagship Pioneering, Indiana blog main, Indiana top stories, Industry, Life Sciences, National blog main, National top stories, new york, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories, startups, VC